

Mirena® (levonorgestrel-releasing intrauterine system) – Expanded indication

- On August 12, 2022, the <u>FDA approved</u> Bayer Healthcare's <u>Mirena (levonorgestrel-releasing intrauterine system)</u>, for prevention of pregnancy for up to 8 years; replace after the end of the eighth year.
 - Mirena was previously approved for prevention of pregnancy for up to 7 years.
- Mirena is also approved for the treatment of heavy menstrual bleeding for up to 5 years in women
 who choose to use intrauterine contraception as their method of contraception; replace after the
 end of the fifth year if continued treatment of heavy menstrual bleeding is needed.
- The approval of Mirena for the expanded indication was based on Mirena Extension Trial, an open-label, uncontrolled study in 362 women using Mirena. The pregnancy rate calculated as the Pearl Index (PI) was the primary efficacy endpoint used to assess contraceptive efficacy. The cumulative 3-year pregnancy rate for Years 6, 7 and 8 was estimated by the Kaplan-Meier method
 - The PI for the 8th year of use based on no pregnancies occurring during Year 8 and within 7 days after Mirena removal or expulsion and 2,534 evaluable cycles was 0.00 with a 95% upper confidence limit of 1.90.
 - Based on 2 pregnancies (1 in Year 6 and 1 in Year 7) and 10,216 exposure cycles, the cumulative pregnancy rate at the end of the 3-year period of extended use (Years 6, 7 and 8) was 0.68% with a 95% upper confidence limit of 2.71%.
- Mirena contains 52 mg of levonorgestrel (LNG) released in vivo, at a rate of approximately 21 mcg/day after 24 days. This rate decreases progressively to approximately 11 mcg/day after 5 years and 7 mcg/day after 8 years. For contraception, remove Mirena by the end of the eighth year and replace at the time of removal with a new Mirena if continued use is desired.
- Refer to the Mirena drug label for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.